Soft Tissue Sarcoma

2023 - 12 - 19

Ozuriftamab vedotin by BioAtla for Soft Tissue Sarcoma: Likelihood ... (pharmaceutical-technology.com)

The drug candidate acts by targeting tyrosine-protein kinase transmembrane receptor (ROR2). It is developed based on conditionally active biologics (CAB) ...

Mecbotamab vedotin by BioAtla for Soft Tissue Sarcoma: Likelihood ... (pharmaceutical-technology.com)

The drug candidate acts by targeting AXL receptor tyrosine kinase. The drug candidate is developed based on conditionally active biologics (CAB) platforms.

Mipasetamab uzoptirine by ADC Therapeutics for Soft Tissue ... (pharmaceutical-technology.com)

ADCT-601(BGB-601) is under development for the treatment of solid tumor, malignant fibrous histiocytoma. The drug candidate is an antibody drug conjugate ...

Explore the last week